Kyverna Therapeutics reported positive registrational data from a pivotal study of its patient‑specific CD19 CAR‑T therapy in stiff person syndrome (SPS), a rare autoimmune movement disorder. The company said the trial met the primary endpoint and all secondary endpoints, showing clinically meaningful improvements in mobility and stiffness, and intends to file for FDA approval in the first half of 2026. Kyverna characterized the readout as the first pivotal success for a CAR‑T therapy in an autoimmune indication, citing the unmet need and lack of approved options for SPS. The company said safety was consistent with expectations for autologous CAR‑T, and it will present full data in upcoming regulatory and scientific forums. If approved, the therapy would be a precedent‑setting application of CAR‑T beyond oncology and would accelerate interest in cell therapies for autoimmune diseases.